VIROMED MEDICAL NA O.N. (VME) - Net Assets
Based on the latest financial reports, VIROMED MEDICAL NA O.N. (VME) has net assets worth €10.47 Million EUR (≈ $12.25 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€13.91 Million ≈ $16.27 Million USD) and total liabilities (€3.44 Million ≈ $4.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of VIROMED MEDICAL NA O.N. for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €10.47 Million |
| % of Total Assets | 75.28% |
| Annual Growth Rate | -19.5% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28.72 |
VIROMED MEDICAL NA O.N. - Net Assets Trend (2022–2025)
This chart illustrates how VIROMED MEDICAL NA O.N.'s net assets have evolved over time, based on quarterly financial data. Check VIROMED MEDICAL NA O.N. tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for VIROMED MEDICAL NA O.N. (2022–2025)
The table below shows the annual net assets of VIROMED MEDICAL NA O.N. from 2022 to 2025. For live valuation and market cap data, see VME company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €10.47 Million ≈ $12.25 Million |
+12.98% |
| 2024-12-31 | €9.27 Million ≈ $10.84 Million |
-53.58% |
| 2023-12-31 | €19.97 Million ≈ $23.35 Million |
-0.55% |
| 2022-12-31 | €20.08 Million ≈ $23.48 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to VIROMED MEDICAL NA O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1208064314.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €22.72 Million | 216.92% |
| Total Equity | €10.47 Million | 100.00% |
VIROMED MEDICAL NA O.N. Competitors by Market Cap
The table below lists competitors of VIROMED MEDICAL NA O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Formuepleje Limittellus
CO:FPILIM
|
$156.21 Million |
|
Trabzonspor Sportif Yatirim ve Futbol Isletmeciligi Ticaret AS
IS:TSPOR
|
$156.22 Million |
|
Hoang Huy Investment Services JSC
VN:HHS
|
$156.25 Million |
|
Kapston Services Limited
NSE:KAPSTON
|
$156.30 Million |
|
Doktas Dokumculuk Ticaret ve Sanayi AS
IS:DOKTA
|
$156.17 Million |
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
$156.10 Million |
|
Humasis Co. Ltd
KQ:205470
|
$156.05 Million |
|
Alcatel Lucent Teletas Telekomunikasyon AS
IS:ALCTL
|
$156.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VIROMED MEDICAL NA O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,271,143 to 10,474,092, a change of 1,202,949 (13.0%).
- Net income of 604,514 contributed positively to equity growth.
- Other factors increased equity by 598,435.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €604.51K | +5.77% |
| Other Changes | €598.43K | +5.71% |
| Total Change | €- | 12.98% |
Book Value vs Market Value Analysis
This analysis compares VIROMED MEDICAL NA O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 7.65x to 15.32x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | €0.99 | €7.55 | x |
| 2024-12-31 | €0.46 | €7.55 | x |
| 2025-12-31 | €0.49 | €7.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently VIROMED MEDICAL NA O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.77%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.88%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.33x
- Recent ROE (5.77%) is above the historical average (-7.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -0.80% | 0.00% | 0.00x | 1.01x | €-2.17 Million |
| 2023 | -0.55% | 0.00% | 0.00x | 1.02x | €-2.11 Million |
| 2024 | -33.36% | -274.95% | 0.08x | 1.45x | €-4.02 Million |
| 2025 | 5.77% | 11.88% | 0.37x | 1.33x | €-442.89K |
Industry Comparison
This section compares VIROMED MEDICAL NA O.N.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $50,900,811,594
- Average return on equity (ROE) among peers: -43.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VIROMED MEDICAL NA O.N. (VME) | €10.47 Million | -0.80% | 0.33x | $156.19 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.50 Billion | 7.19% | 0.43x | $168.08K |
| BIORETEC OY (0TN) | $9.76 Million | -97.14% | 0.20x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $432.90 Billion | 11.47% | 0.43x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $683.20 Million | 13.73% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $2.77 Million | -198.14% | 0.62x | $28.30 Million |
| Medtronic PLC (2M6) | $52.72 Billion | 9.56% | 0.73x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.81 Billion | -73.53% | 0.02x | $328.75 Million |
| AVITA Medical Inc (51KB) | $115.66 Million | -22.98% | 0.09x | $172.49 Million |
| BRAINCOOL AB (5YL) | $45.23 Million | -85.67% | 1.20x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.22 Billion | -2.23% | 0.20x | $107.57 Million |
About VIROMED MEDICAL NA O.N.
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.